Analysis and Perspectives

Nov 27, 2023

The FDA has granted label extensions for two of the most vital global cancer drugs—Merck’s Keytruda and Pfizer and Astellas’ Xtandi.

Nov 24, 2023

On October 31, FDA approved Cosentyx hidradenitis suppurativa treatment, marking first approval of new biologic in nearly a decade.

Nov 22, 2023

In recent years, the joint reconstruction devices market within the realm of orthopedics has undergone a profound evolution, owing to the technological advancements and innovations that have revolutionized treatment modalities and patient outcomes to a much greater extent. The intersection of innovative technologie...

Nov 20, 2023

Within a three-day period, Phathom Pharmaceuticals achieves dual FDA approvals for Voquezna, its groundbreaking heartburn medication.

Nov 15, 2023

Rehabilitation equipment, a cornerstone in the realm of healthcare, has undergone a remarkable evolution over the years, propelled by the rising demand and their potential to improve patient outcomes and restore quality of life. From rudimentary tools and manual therapies to the present-day sophisticated, technolog...

Nov 13, 2023

Servier’s Tibsovo has received FDA approval for patients diagnosed with R/R myelodysplastic syndromes that exhibit an IDH1 mutation.

Nov 10, 2023

Roche’s Vabysmo secures new FDA nod for retinal vein occlusion treatment, intensifying competition with Regeneron and Bayer’s Eylea.

Nov 08, 2023

The Energy-Based Aesthetic Devices market stands at the forefront of the evolving landscape of cosmetic treatments, offering a comprehensive range of solutions for individuals seeking non-invasive and minimally invasive procedures to enhance their appearance. Over the past few years, intense advancements in technol...

Nov 06, 2023

Coherus and Junshi received FDA approval for Loqtorzi, marking significant milestone as first-ever nasopharyngeal carcinoma treatment.

Nov 03, 2023

The dynamics of the Niemann-Pick Disease Type C treatment market are expected to change owing to the emerging therapies by key companies.